脊髄性筋萎縮症（SMA）治療の世界市場（～2026年）

• 英文タイトル：Global Spinal Muscular Atrophy (SMA) Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04710
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、91ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は脊髄性筋萎縮症（SMA）治療のグローバル市場について調査・分析したレポートです。種類別（I型脊髄性筋萎縮症（SMA）、II型脊髄性筋萎縮症（SMA）、III型脊髄性筋萎縮症（SMA））市場規模、用途別（病院、外来外科センター、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別脊髄性筋萎縮症（SMA）治療の競争状況、市場シェア
・世界の脊髄性筋萎縮症（SMA）治療市場：種類別市場規模 2015年-2020年（I型脊髄性筋萎縮症（SMA）、II型脊髄性筋萎縮症（SMA）、III型脊髄性筋萎縮症（SMA））
・世界の脊髄性筋萎縮症（SMA）治療市場：種類別市場規模予測 2021年-2026年（I型脊髄性筋萎縮症（SMA）、II型脊髄性筋萎縮症（SMA）、III型脊髄性筋萎縮症（SMA））
・世界の脊髄性筋萎縮症（SMA）治療市場：用途別市場規模 2015年-2020年（病院、外来外科センター、診断センター、その他）
・世界の脊髄性筋萎縮症（SMA）治療市場：用途別市場規模予測 2021年-2026年（病院、外来外科センター、診断センター、その他）
・北米の脊髄性筋萎縮症（SMA）治療市場分析：米国、カナダ
・ヨーロッパの脊髄性筋萎縮症（SMA）治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの脊髄性筋萎縮症（SMA）治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の脊髄性筋萎縮症（SMA）治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの脊髄性筋萎縮症（SMA）治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Pfizer、Isis Pharmaceuticals、Biogen Idec、Boehringer Ingelheim、F. Hoffmann-La Roche、Regeneron Pharmaceuticals
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Spinal muscular atrophy (SMA) refers to a group of inherited diseases that affects the functioning of muscles because of deterioration.
North America dominates the global market for SMA treatment due to the high prevalence of SMA and increased adoption of SMA treatment options in the region.

Market Analysis and Insights: Global Spinal Muscular Atrophy (SMA) Treatment Market
The global Spinal Muscular Atrophy (SMA) Treatment market size is projected to reach US$ 943.7 million by 2026, from US$ 874.6 million in 2020, at a CAGR of 7.3%% during 2021-2026.

Global Spinal Muscular Atrophy (SMA) Treatment Scope and Market Size
Spinal Muscular Atrophy (SMA) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Spinal Muscular Atrophy (SMA) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Pfizer
Isis Pharmaceuticals
Biogen Idec
Boehringer Ingelheim
F. Hoffmann-La Roche
Regeneron Pharmaceuticals
…

Market segment by Type, the product can be split into
Type I Spinal Muscular Atrophy (SMA)
Type II Spinal Muscular Atrophy (SMA)
Type III Spinal Muscular Atrophy (SMA)
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Treatment Revenue
1.4 Market by Type
1.4.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Type I Spinal Muscular Atrophy (SMA)
1.4.3 Type II Spinal Muscular Atrophy (SMA)
1.4.4 Type III Spinal Muscular Atrophy (SMA)
1.5 Market by Application
1.5.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Diagnostic Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Perspective (2015-2026)
2.2 Global Spinal Muscular Atrophy (SMA) Treatment Growth Trends by Regions
2.2.1 Spinal Muscular Atrophy (SMA) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Spinal Muscular Atrophy (SMA) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Spinal Muscular Atrophy (SMA) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Spinal Muscular Atrophy (SMA) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Market Size
3.1.1 Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Revenue (2015-2020)
3.1.2 Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Spinal Muscular Atrophy (SMA) Treatment Market Concentration Ratio
3.2.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Treatment Revenue in 2019
3.3 Spinal Muscular Atrophy (SMA) Treatment Key Players Head office and Area Served
3.4 Key Players Spinal Muscular Atrophy (SMA) Treatment Product Solution and Service
3.5 Date of Enter into Spinal Muscular Atrophy (SMA) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Spinal Muscular Atrophy (SMA) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)
5.2 Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
6.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in North America (2019-2020)
6.3 North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
6.4 North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
7.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Europe (2019-2020)
7.3 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
7.4 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

8 China
8.1 China Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
8.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in China (2019-2020)
8.3 China Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
8.4 China Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
9.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Japan (2019-2020)
9.3 Japan Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
9.4 Japan Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
10.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

11 India
11.1 India Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
11.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in India (2019-2020)
11.3 India Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
11.4 India Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
12.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Spinal Muscular Atrophy (SMA) Treatment Introduction
13.1.4 Pfizer Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Isis Pharmaceuticals
13.2.1 Isis Pharmaceuticals Company Details
13.2.2 Isis Pharmaceuticals Business Overview
13.2.3 Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Introduction
13.2.4 Isis Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
13.2.5 Isis Pharmaceuticals Recent Development
13.3 Biogen Idec
13.3.1 Biogen Idec Company Details
13.3.2 Biogen Idec Business Overview
13.3.3 Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Introduction
13.3.4 Biogen Idec Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
13.3.5 Biogen Idec Recent Development
13.4 Boehringer Ingelheim
13.4.1 Boehringer Ingelheim Company Details
13.4.2 Boehringer Ingelheim Business Overview
13.4.3 Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Introduction
13.4.4 Boehringer Ingelheim Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
13.4.5 Boehringer Ingelheim Recent Development
13.5 F. Hoffmann-La Roche
13.5.1 F. Hoffmann-La Roche Company Details
13.5.2 F. Hoffmann-La Roche Business Overview
13.5.3 F. Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Introduction
13.5.4 F. Hoffmann-La Roche Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
13.5.5 F. Hoffmann-La Roche Recent Development
13.6 Regeneron Pharmaceuticals
13.6.1 Regeneron Pharmaceuticals Company Details
13.6.2 Regeneron Pharmaceuticals Business Overview
13.6.3 Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Introduction
13.6.4 Regeneron Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
13.6.5 Regeneron Pharmaceuticals Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Spinal Muscular Atrophy (SMA) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Treatment Revenue
Table 3. Ranking of Global Top Spinal Muscular Atrophy (SMA) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Type I Spinal Muscular Atrophy (SMA)
Table 6. Key Players of Type II Spinal Muscular Atrophy (SMA)
Table 7. Key Players of Type III Spinal Muscular Atrophy (SMA)
Table 8. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Regions (2015-2020)
Table 12. Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Spinal Muscular Atrophy (SMA) Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Spinal Muscular Atrophy (SMA) Treatment Players
Table 19. Global Spinal Muscular Atrophy (SMA) Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Players (2015-2020)
Table 21. Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Spinal Muscular Atrophy (SMA) Treatment as of 2019)
Table 22. Global Spinal Muscular Atrophy (SMA) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Spinal Muscular Atrophy (SMA) Treatment Product Solution and Service
Table 25. Date of Enter into Spinal Muscular Atrophy (SMA) Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Share by Type (2015-2020)
Table 29. Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Share by Application (2015-2020)
Table 31. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Spinal Muscular Atrophy (SMA) Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Spinal Muscular Atrophy (SMA) Treatment Market Share (2019-2020)
Table 35. North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Spinal Muscular Atrophy (SMA) Treatment Market Share by Type (2015-2020)
Table 37. North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Spinal Muscular Atrophy (SMA) Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Spinal Muscular Atrophy (SMA) Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Spinal Muscular Atrophy (SMA) Treatment Market Share (2019-2020)
Table 41. Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Spinal Muscular Atrophy (SMA) Treatment Market Share by Type (2015-2020)
Table 43. Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Spinal Muscular Atrophy (SMA) Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Spinal Muscular Atrophy (SMA) Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Spinal Muscular Atrophy (SMA) Treatment Market Share (2019-2020)
Table 47. China Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Spinal Muscular Atrophy (SMA) Treatment Market Share by Type (2015-2020)
Table 49. China Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Spinal Muscular Atrophy (SMA) Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Spinal Muscular Atrophy (SMA) Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Spinal Muscular Atrophy (SMA) Treatment Market Share (2019-2020)
Table 53. Japan Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Spinal Muscular Atrophy (SMA) Treatment Market Share by Type (2015-2020)
Table 55. Japan Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Spinal Muscular Atrophy (SMA) Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Spinal Muscular Atrophy (SMA) Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Spinal Muscular Atrophy (SMA) Treatment Market Share (2019-2020)
Table 59. Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Spinal Muscular Atrophy (SMA) Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Spinal Muscular Atrophy (SMA) Treatment Market Share (2019-2020)
Table 65. India Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Spinal Muscular Atrophy (SMA) Treatment Market Share by Type (2015-2020)
Table 67. India Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Spinal Muscular Atrophy (SMA) Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Spinal Muscular Atrophy (SMA) Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Spinal Muscular Atrophy (SMA) Treatment Market Share (2019-2020)
Table 71. Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Share by Application (2015-2020)
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Product
Table 78. Pfizer Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020) (Million US$)
Table 79. Pfizer Recent Development
Table 80. Isis Pharmaceuticals Company Details
Table 81. Isis Pharmaceuticals Business Overview
Table 82. Isis Pharmaceuticals Product
Table 83. Isis Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020) (Million US$)
Table 84. Isis Pharmaceuticals Recent Development
Table 85. Biogen Idec Company Details
Table 86. Biogen Idec Business Overview
Table 87. Biogen Idec Product
Table 88. Biogen Idec Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020) (Million US$)
Table 89. Biogen Idec Recent Development
Table 90. Boehringer Ingelheim Company Details
Table 91. Boehringer Ingelheim Business Overview
Table 92. Boehringer Ingelheim Product
Table 93. Boehringer Ingelheim Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020) (Million US$)
Table 94. Boehringer Ingelheim Recent Development
Table 95. F. Hoffmann-La Roche Company Details
Table 96. F. Hoffmann-La Roche Business Overview
Table 97. F. Hoffmann-La Roche Product
Table 98. F. Hoffmann-La Roche Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020) (Million US$)
Table 99. F. Hoffmann-La Roche Recent Development
Table 100. Regeneron Pharmaceuticals Company Details
Table 101. Regeneron Pharmaceuticals Business Overview
Table 102. Regeneron Pharmaceuticals Product
Table 103. Regeneron Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020) (Million US$)
Table 104. Regeneron Pharmaceuticals Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Type I Spinal Muscular Atrophy (SMA) Features
Figure 3. Type II Spinal Muscular Atrophy (SMA) Features
Figure 4. Type III Spinal Muscular Atrophy (SMA) Features
Figure 5. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Ambulatory Surgical Centers Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Others Case Studies
Figure 10. Spinal Muscular Atrophy (SMA) Treatment Report Years Considered
Figure 11. Global Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Regions: 2020 VS 2026
Figure 13. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Players in 2019
Figure 16. Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Spinal Muscular Atrophy (SMA) Treatment as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Treatment Revenue in 2019
Figure 18. North America Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed

以下、関連資料のご紹介

脊髄性筋萎縮症の世界市場（～2026年）

Global Spinal Muscular Atrophy Market Size, Status and Forecast 2020-2026
MRC2-11QY04711 2020年11月20日 96Pages
当調査資料は脊髄性筋萎縮症のグローバル市場について調査・分析したレポートです。種類別（初期段階の候補者、後期段階の候補者）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

オピオイド誘発性便秘（OIC）治療の世界市場（～2026年）

Global Opioid-Induced Constipation (OIC) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04062 2020年11月20日 99Pages
当調査資料はオピオイド誘発性便秘（OIC）治療のグローバル市場について調査・分析したレポートです。種類別（経口、非経口（皮下注射））市場規模、用途別（ドラッグストア、独立型薬局、病院薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...

自閉症スペクトラム障害（ASD）治療の世界市場（～2026年）

Global Autism Spectrum Disorder (ASD) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY10928 2020年11月25日 94Pages
当調査資料は自閉症スペクトラム障害（ASD）治療のグローバル市場について調査・分析したレポートです。種類別（自閉症、アスペルガー症候群、広汎性発達障害、小児期崩壊性障害）市場規模、用途別（病院・クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア...

ミトコンドリアミオパチー診断・治療の世界市場（～2026年）

Global Mitochondrial Myopathy Diagnosis & Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12711 2020年11月25日 96Pages
当調査資料はミトコンドリアミオパチー診断・治療のグローバル市場について調査・分析したレポートです。種類別（筋肉生検、血液酵素検査、遺伝子検査）市場規模、用途別（病院、クリニック、疾病研究・開発機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア...

男性不妊症診断・治療の世界市場（～2026年）

Global Male Infertility Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12577 2020年11月25日 97Pages
当調査資料は男性不妊症診断・治療のグローバル市場について調査・分析したレポートです。種類別（医薬品市場、外科市場、生殖補助医療（ART）市場）市場規模、用途別（病院・クリニック、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本...

前立腺がん診断・治療の世界市場（～2026年）

Global Prostate Cancer Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04386 2020年11月20日 133Pages
当調査資料は前立腺がん診断・治療のグローバル市場について調査・分析したレポートです。種類別（前立腺特異抗原検査（PSA）、直腸指診（DRE））市場規模、用途別（病院、診断クリニック、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、...

巣状分節性糸球体硬化症（FSGS）治療の世界市場（～2026年）

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11975 2020年11月25日 94Pages
当調査資料は巣状分節性糸球体硬化症（FSGS）治療のグローバル市場について調査・分析したレポートです。種類別（薬物療法、透析、腎移植）市場規模、用途別（一次FSGS、二次FSGS）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国...

女性用不妊症診断・治療の世界市場（～2026年）

Global Female Infertility Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11927 2020年11月25日 130Pages
当調査資料は女性用不妊症診断・治療のグローバル市場について調査・分析したレポートです。種類別（治療剤・薬品、手術、子宮内授精（IUI）、生殖補助医療（ART））市場規模、用途別（病院・クリニック、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロ...

髄膜炎診断・治療の世界市場（～2026年）

Global Meningitis Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12650 2020年11月25日 91Pages
当調査資料は髄膜炎診断・治療のグローバル市場について調査・分析したレポートです。種類別（血液培養、イメージング、腰椎穿刺）市場規模、用途別（病院・クリニック、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド...

経口血糖降下薬（OAD）治療の世界市場（～2026年）

Global Oral Antidiabetic (OAD) Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04077 2020年11月20日 99Pages
当調査資料は経口血糖降下薬（OAD）治療のグローバル市場について調査・分析したレポートです。種類別（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）市場規模、用途別（病院、クリニック、糖尿病治療センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、...

脊髄性筋萎縮症の世界市場（～2026年） Market Analysis and Insights: Global Spinal Muscular Atrophy Market The global Spinal Muscular Atrophy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Spinal Muscular Atrophy Scope and Market Size Spinal Muscular Atrop…
多系統萎縮症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Multiple System Atrophy Therapeutics Market The global Multiple System Atrophy Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Multiple System Atrophy Therapeutics Scop…
ベッカー型筋ジストロフィー治療薬の世界市場（～2026年） Market Analysis and Insights: Global Becker Muscular Dystrophy Drug Market The global Becker Muscular Dystrophy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Becker Muscular Dystrophy Drug Scope and Market Size …
脳脊髄液（CSF）管理の世界市場（～2026年） CSF is a clear, colorless body fluid found in the brain and spinal cord. CSF occupies the subarachnoid space (between the arachnoid mater and the pia mater) and the ventricular system around and inside the brain and spinal cord. Market Analysis and Insights: Global Cerebral Spinal Fluid (CSF) Manage…
脊椎手術の世界市場（～2026年） Back pain is a symptom of medical condition and the most common cause of back pain is a condition called intervertebral disc degeneration which means that the disc located between the vertebrae of the spine are breaking down with age. An increasing preference for Minimally Invasive Spinal Surgery, l…